Small Cap Feast

Small Cap Feast – 12 February 2020

Set Menu AIM:

Total number of AIM Companies (Incl Susp):

Total number of AIM Companies trading: *
* As at

Set Menu NEX Growth:

Total number of NEX Growth Market Companies (Incl Susp): *

Total number of NEX Growth Market Companies trading: *
* As at

Set Menu Standard List:

Total number of Standard List Companies (Incl Susp): *

Total number of Standard List Companies trading: *
* As at

Dish of the Day:

Unconditional Dealings commence in Calisen (CLSN.L) main mkt premium., raising £300m. Mkt cap £1.32bn.


Off the Menu:

No Leavers Today


Dish of the Day:

Off the Menu:

What’s Cooking in the IPO Kitchen?


Intention to float by Gemfields Group. No Capital Raise. Currently listed on JSE. (GML:JNB) at circa £122m.  The Group’s key producing assets, the Kagem emerald mine in Zambia  (believed to be the world’s single largest producing emerald mine) and the Montepuez ruby mine in Mozambique (one of the most significant recently discovered ruby deposits in the world), are both expected to have long mine-lives with potential for expansion. Also owns the  Faberge brand. Due Valentines Day 2020.

Main Market (Standard List)

The Proof Of Trust has announced its intention to list on the Standard Market.  The Blockchain based business, owns patents to a protocol which facilitates dispute resolution based upon smart contract disputes.  Transaction details TBC.

Main Market (Premium)

DRI Healthcare—investment company focused on investments in healthcare Royalty Assets  looking to raise $350m. Due 11 Mar.

Ninety One –proposed demerger and public listing of  Investec’s  global asset management business on LSE and JSE. 30 Sep 2019 AUM £121bn. Sale of existing shares. Expected free float of >60%. Due 16 march.

Cabot Square—Closed ended investment fund focussed on alternative assets and asset manager. Looking to raise £200m.  Will target investment opportunities that are expected to generate an attractive risk adjusted return and that can also make a positive ESG impact by focusing on some of the biggest challenges facing societies and economies.  Due 14 Feb.

The Global Sustainable Farmland Income Trust will invest in a diversified portfolio of operational farmland assets located in major agricultural markets including the United States, Europe, New Zealand, Australia and certain countries within Latin and South America. Raising up to $300m.   Due 28 February.

Investment firm Nippon Active Value fund is seeking to raise up to £200m at an issue price of 100p per share via an IPO.   The company aims to invest in a portfolio of quoted Japanese stocks with market capitalisations of up to $1bn.   First day of dealings expected early February.

NEX Exchange

Zapp Scooters, a developer and manufacturer of electric two-wheeled vehicles announced its intention to IPO on the NEX Exchange Growth Market.  The Company intends to raise up to £3.5m. Admission is expected to occur on NEX in February 2020.


Breakfast Buffet

Oncimmune Holdings (ONC.L) 31.5p £19.9m

The leading global immunodiagnostics group, today announces its half year results for the six months ended 30 November 2019.

Biodesix to launch EarlyCDT Lung in US by early March 2020

Service contract signed with a large pharmaceutical group

In late stage talks on multiple potential service contracts.

Revenue for the period was £0.31m. Cash £7.5m

Total administrative expenses were £5.11m (H1 2018: £2.63m); of which c.£1.3m relates to reshaping the business (£0.7m relate to the Biodesix and Protagen Diagnostics transactions and £0.6m relates to increased staff costs); a further £0.7m relates to the IPF credit facility and increased patent costs as the Protagen patent estate was integrated.

 The implementation of an ongoing cost reduction programme post the period has delivered annual cost savings of c.£1.0m, with the sale of the US subsidiary’s laboratory to Biodesix expected to contribute further annual cost savings of c.£2.2m.

 R&D costs were £1.01m.


Fox Marble (FOX.L) 2.25p £5.9m

 The  company focused on marble quarrying and processing in Kosovo and the Balkans region announces that it has entered into an agreement with EBA Sh.p.K with the intention to provide processed marble in the form of tiles, stair treads and window lintels. 


EBA Sh.p.K is a local architect and construction firm based in Kosovo, and the products are destined for use in construction projects within Kosovo. The material selected for these items is Flora, Alexandrian White and Illirico Bianco.

The stone will be processed at Fox Marble’s Lipjan factory, from existing blocks of Illirico Bianco, Flora and Alexandrian White. The agreement has no minimum order value, but pricing is based on a minimum volume of 2,000 square metres, which the Company expects to supply over the course of this financial year.


Frontier IP Group (FIPP.L) 65p £32.9m

 Frontier IP, a specialist in commercialising intellectual property, has raised its equity stake in portfolio company Celerum Limited from 10 per cent to 33.8 per cent. The increase is in return for an investment of £25,000, converting a previous loan of £21,818 into equity, and for providing £50,000 worth of additional strategic, business and hands-on software development services. 

Celerum, a spin out from Robert Gordon University (“RGU”), Aberdeen, is developing novel artificial intelligence to help businesses improve the operational efficiency of logistics and supply chains. It also has the potential to  tackle a host of other complex scientific, engineering and industrial challenges. Frontier IP is stepping up its support for the Company in response to increased industry interest.


Scapa Group (SCPA.L) 193.5p £300m

Update on current trading ahead of its financial year-end on 31 March 2020.

Revenue c.£306m, broadly in line with market expectations. However, trading profit is now expected to be approximately £28m, significantly below consensus. Healthcare revenue is estimated to be approximately £139m, slightly ahead of market expectations and greater than last year despite the loss of the ConvaTec contract. Healthcare trading profit is expected to be lower than consensus, reflecting slower progress in reducing costs than expected at the time of the interim results. Industrial revenue is expected to be approximately £168m, which is slightly below market expectations but has a material impact on Group trading profit, primarily the result of adverse macroeconomic conditions. Scapa is focused on rigorous execution of the strategy as it continues to increase efficiency and convert its pipeline of opportunities to improve sales and margin performance. Expects the macro environment to remain challenging in some of the industrial markets in which it operates.


RWS Holdings (RWS.L) 601.5p £1.65bnm

AGM Statement from the language, intellectual property support services and localization providers. “The financial year ended 30 September 2019 was an excellent year for RWS, with all three divisions delivering record results, enabling the Group to maintain its unparalleled record of 16 years of unbroken growth in revenues, profits and dividends since flotation in 2003. This achievement was recognized when RWS was named Company of the Year at the 2019 AIM Awards.”

Current trading and outlook

“We have continued to build on our momentum in the first few months of the 2020 financial year, with several excellent new contract wins, particularly within our IP Services division, leaving us on course to deliver full year results in line with the Board’s underlying expectations, notwithstanding the recent currency headwinds.”


SolGold (SOLG.L) 18.25p £351m

Update on exploration at its 100% owned Timbara Project in Southern Ecuador. The project is held in SolGold’s 100% owned subsidiary Green Rock Resources S.A.

Ø The Timbara project is of Jurassic age similar to nearby the Fruta del Norte, Mirador and Santa Barbara deposits.

Mineralisation mapped over a 600m strike length demonstrates strong gold grades and remains open in both directions at Timbara 2. Mineralisation occurs within an 18m wide northwest trending silicified zone, hosting polymetallic quartz veins. Rock saw channel sampling confirms the prospectivity of the Timbara 2 zone, with initial rock saw channel samples returning:

7.7m @ 6.63 g/t Au (northern stream outcrops) -2m @ 5.16 g/t Au (southern stream outcrops)

The mineralisation at the southern stream outcrop remains open at both ends.

 Field teams are continuing with clearing to create additional outcrop exposures for further mapping and sampling.


Phoenix Copper (PXC.L) 10.5p £4.5m

Results of two years of independent baseline environmental data collection and monitoring at the Empire Mine, Idaho USA.  The results of the monitoring will be used directly for environmental permitting and the continued development of the Plan of Operations for all future mining activity, including Red Star and the Empire open-pit copper oxide deposit.

No critical habitat for threatened or endangered plant or wildlife was identified within the project area.

Surface and groundwater studies indicate no impacts from legacy mining operations. No significant cultural or archaeological artefacts identified in the project area

No Sage Grouse or Sage Grouse leks (breeding sites) were identified at or near the project area.

The full Plant and Wildlife reports, archaeological reports, and hydrological reports can be viewed on the Company’s website at in the name of Konnex Resources Inc, the subsidiary local operating company of the Company


7digital (7Dig.L) 0.5p £11.3m

 The global leader in B2B end-to-end digital music solutions, is pleased to announce that its music platform-as-a-service will power jazzed, the world’s first dedicated audio-visual streaming service for jazz and jazz-influenced music.

jazzed is a multi-tier jazz streaming subscription service which has been developed by ETA Productions Ltd, a specialist in creating new digital media platforms for entertainment markets. Launched today, it offers a highly curated music, video and editorial experience for the jazz fan, featuring over 5m tracks and unique individual channels. Under the terms of the initial 12 month contract, which includes set-up, monthly and usage-based content fees, jazzed will use 7digital’s API and platform access, playlist tools, reporting services and catalogue management. This will allow jazzed users to stream music from 7digital’s extensive catalogue of jazz tracks. jazzed offers an ad-funded freemium version featuring 10 hand-curated audio channels and a selection of video content, and a £5.99 monthly subscription-based tier with over 40 channels and exclusive video content.


88 Energy (88E.L) 1.175p £83.5m

Update related to operations for the upcoming Charlie-1 appraisal well, on the North Slope of Alaska.


  • Ice road now >80% complete

Permit to Drill approved for Charlie-1 appraisal well

  • Spud on track for late February


Craven House Capital (CRV.L) 3.85p £10.3m

$1.9m placing at $10. Whilst this does represent a 237% premium to the closing mid-market price on 11 February 2020, it represents a 1.1% premium to the last audited NAV per share of $9.89 as at 31 May 2019.

The proceeds of the Placing Shares will be used to undertake investments further to the Company’s investment strategy.


Head Chef:

Derren Nathan
0203 764 2344

*A corporate client of Hybridan LLP


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email with “unsubscribe me”.